1342834-87-0 Usage
Chemical Family
Belongs to the pyrrolidin-2-one family
Structure
Contains a 1H-pyrazol-1-yl group, a tetramethyl-1,3,2-dioxaborolan-2-yl group, and a pyrrolidin-2-one group
Potential Applications
May have potential applications in pharmaceuticals, agrochemicals, and material sciences
Research and Testing
Further research and testing are needed to fully understand the properties and potential uses of this chemical compound
Molecular Weight
Approximately 315.16 g/mol
Appearance
Likely a solid or crystalline substance (based on typical properties of similar compounds)
Solubility
Solubility in organic solvents such as ethanol, methanol, or dimethyl sulfoxide (DMSO) is possible, but specific solubility data is not provided
Stability
Stability under various conditions (e.g., temperature, pH, light exposure) is not provided, and further research is needed to determine stability
Reactivity
Reactivity with other chemicals, catalysts, or reagents is not provided, and further research is needed to determine reactivity
Check Digit Verification of cas no
The CAS Registry Mumber 1342834-87-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,4,2,8,3 and 4 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1342834-87:
(9*1)+(8*3)+(7*4)+(6*2)+(5*8)+(4*3)+(3*4)+(2*8)+(1*7)=160
160 % 10 = 0
So 1342834-87-0 is a valid CAS Registry Number.
1342834-87-0Relevant academic research and scientific papers
Inhibitors of Protein Tyrosine Kinase Activity
-
, (2011/10/31)
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.
